Categories
Change Password!
Reset Password!
Mepolizumab can be effective in patients with severe asthma irrespective
of common comorbidities, like obesity,
upper and lower airway diseases, and mood ailments.
The use of mepolizumab presented real-world clinical benefits in patients with severe asthma and linked comorbidities, a novel study published in the journal- Annals of Allergy, Asthma & Immunology revealed. This retrospective analysis by Thomas Casale et al. described the real-world efficacy of mepolizumab (humanized monoclonal antibody) in people with severe asthma stratified by common overlapping comorbidities.
A total of 639 patients with asthma initiating mepolizumab treatment were included. Eligible individuals were divided into 7 comorbidity subgroups: obesity, atopic disease, nasal polyposis, sinus and respiratory infections, depression or anxiety and chronic obstructive pulmonary disease (COPD) during the 12-month baseline period. Outcomes included asthma attacks and its associated health care resource utilization through the 12-month baseline and follow-up phases.
Atopic diseases (73.2%) was the most common comorbidity, followed by respiratory infections (55.6%) and sinus infection (45.1%). A substantial decline of 38% to 55% in asthma attacks and 57% to 83% in exacerbations needing hospital admission during the follow-up versus baseline was observed, except for the attacks needing hospital admission in the nasal polyposis subgroup.
The number of oral
corticosteroids claims (on an average) considerably dropped by 29% to 38%, and;
39% to 47% of patients had ≥ 50% oral corticosteroid dose lessening during the
study period. The exacerbation-linked health care resource utilization was
reduced significantly. Thus, patients having severe asthma attain real-world
clinical benefits with mepolizumab therapy.
Annals of Allergy, Asthma & Immunology
Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities
Thomas Casale et al.
Comments (0)